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Tumor antigen-reactive T cells must enter into an immunosuppressive tumor microenvironment, continue to
produce cytokine and deliver apoptotic death signals to affect tumor regression. Many tumors produce
transforming growth factor beta (TGFβ), which inhibits T cell activation, proliferation and cytotoxicity. In a murine
model of adoptive cell therapy, we demonstrate that transgenic Pmel-1 CD8 T cells, rendered insensitive to TGFβ
by transduction with a TGFβ dominant negative receptor II (DN), were more effective in mediating regression of
established B16 melanoma. Smaller numbers of DN Pmel-1 T cells effectively mediated tumor regression and
retained the ability to produce interferon-γ in the tumor microenvironment. These results support efforts to
incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer.Background
Metastatic melanoma continues to be a therapeutic chal-
lenge. Adoptive cell therapy (ACT) using tumor-infiltrating
lymphocytes (TILs) or T cell receptor-engineered lympho-
cytes has produced increased response rates, many clinic-
ally dramatic, but most are partial and patients generally
relapse within a short time frame [1-3]. Factors contribut-
ing to these partial responses include down-regulation
of MHC and antigen presentation by tumor cells, their
resistance to T cell delivered death signals, and tumor
production of immunosuppressive factors such as vas-
cular endothelial growth factor (VEGF), Indoleamine-
pyrrole 2,3-dioxygenase (IDO), IL10 and transforming
growth factor-beta (TGFβ) [4,5].* Correspondence: jeconomou@mednet.ucla.edu
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distribution, and reproduction in any mediumMany reports have shown that melanoma and other
cancers produce TGFβ which in turn promotes tumor
invasion, metastasis and creates an immunosuppressive
microenvironment that inhibits immune effector func-
tion [6,7]. TGFβ inhibits T cell activation, proliferation,
cytotoxicity and promotes T regulatory cell inhibitory
functions [8-11].
Different strategies to circumvent the inhibitory
effects of TGFβ have been employed with varying suc-
cess. The use of a dominant-negative TGFβ receptor II
(DN) as a decoy receptor to render T cells insensitive
to TGFβ signaling allows them to retain proliferative
and cytotoxic functions in the presence of exogenous
TGFβ and to acquire resistance to inhibition by T
regulatory cells (Treg) [12-15]. Transgenic mice with
TGFβ insensitive T cells are resistant to lymphoma
and melanoma tumor challenge [16].
In this study, we used an animal model of ACT in
which antigen-reactive T cells were rendered insensitive
to TGFβ through transduction with a DN TGFβ RII
transgene. These TGFβ-insensitive, antigen-specific Tntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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wards B16 melanoma, most likely due to the ability of
these effector cells to remain active in the tumor
microenvironment.
Materials and methods
Mice and cell lines
C57BL/6 (The Jackson Laboratory) and Pmel-1 (kind gift
from Dr. Nicholas Restifo, Surgery Branch, National
Cancer Institute) [17] mice were bred and kept under
defined-flora pathogen-free conditions at the American
Association for Laboratory Animal Care–approved Ani-
mal Facility of the Division of Experimental Radiation
Oncology, University of California, Los Angeles. The
B16 murine melanoma cell line (American Type Culture
Collection) was maintained in DMEM (Mediatech) with
10% FCS (Omega Scientific) and 1% (v/v) penicillin,
streptomycin, and amphotericin (Omega Scientific).
Western blot analysis for p-SMAD2 expression
Pmel-1 T cells were transduced with DN TGFβ RII (DN)
retrovirus and sorted by FACS to ensure >98% TGFβ RII
expression. Untransduced and DN-transduced pmel-1
cells were incubated in 10 ng/ml TGFβ for 0, 0.5, 1, 6,
24 h prior to protein extraction. Cells were lysed at 4°C
in radioimmuno-precipitation assay (RIPA) buffer
[50 mM Tris–HCl (pH 7.4), 1% NP-40, 0.25% sodium
deoxycholate, 150 mM NaCl] supplemented with one
tablet of protease inhibitor cocktail (Complete Mini;
Roche) and phosphatase inhibitors (Santa Cruz Biotech-
nology, Santa Cruz, CA). A detergent-compatible protein
assay kit (Bio-Rad, Hercules, CA) was used to determine
protein concentration. An aliquot of total protein lysate
was diluted in an equal volume of 2X SDS sample buffer,
boiled for 5 min, and cell lysates were electrophoresed
on 10% SDS-PAGE gels. Western blot was carried out
with anti-phospho-Smad 3 antibody (Cell Signaling
Technology, Danvers, MA) at 1:500 overnight at 4 C,
anti-total-Smad 3 antibody (Cell Signaling) at 1:1000
overnight at 4 C, and anti-β-Actin-HRP antibody
(Sigma, St. Louis, MO) at 1:20,000 for 2 h at room
temperature. Secondary anti-rabbit-HRP (Santa Cruz)
was used at 1:10,000 for 30 min.
Retrovirus production and transduction of pmel-1
splenocytes
The vector containing the dominant negative TGFβ re-
ceptor II, which encodes a truncated receptor lacking
the entire kinase domain and most of juxta-membrane
region was constructed by PCR amplification, using the
TGFβ receptor II cDNA as template [18]. Primers were
designed to include a stop codon after nucleotide 597,
which corresponds to the 10th cytoplasmic codon re-
gion, flanked by Sal I and Bam HI sites. Amplifiedfragment was then inserted into the retroviral vector
MSCV. DN TGFβ RII retrovirus was produced as previ-
ously described [19]. T cells were transduced 48 hours
following polyclonal activation with anti-CD3 and anti-
CD28 (BD Bioscience) coated plates. 2.5 × 106 cells per
well were transduced in 3 ml total volume of virus and
culture media in retronectin coated 24-well plates. Cells
were spinnoculated twice by centrifugation at 1000 × g
for 2 hr at 32°C.
Bone marrow–derived dendritic cells
The generation of dendritic cells from murine bone mar-
row in cultures of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin (IL)-4 was
described previously [20]. Day 8 dendritic cell cultures
were pulsed for 2 h with 1 μg/ml gp10025-33 peptide for
the Pmel-1 adoptive transfer model. Between 5 × 105 and
1 × 106 cells per mouse were injected s.c. in the right
flank.
Pmel-1 adoptive transfer therapy in vivo model
B16 tumors were implanted s.c. as described previously
[20]. When tumors reached 5 to 8 mm in diameter, mice
received a myeloablating regimen of 900 cGy total body
irradiation. The following day, Pmel-1 splenocytes were
adoptively transferred into 8 experimental mice per
group via a lateral tail vein. Subsequently, gp10025-33
peptide-pulsed dendritic cells were given s.c. on the day
of adoptive transfer and 1 week later, in both cases, fol-
lowed by 3 days of daily i.p. administration of 50,000 IU
IL-2. For co-adoptive transfer model, mock and DN-
transduced Pmel-1 were added and mixed at 1:1 ratio
prior to adoptive transfer of 106 activated Pmel-1 fol-
lowed by two rounds of IL-2 administration.
Flow cytometry analysis
Splenocytes and tumor-infiltrating lymphocytes, obtained
from enzymatically digested B16 tumors harvested from
mice as described previously [21], were stained with anti-
bodies to CD8αFITC, TGFβ RIIPE, Thy1.1PerCP, and
CD3APC-Cy7 (BD Bioscience), and analyzed with a FACS-
Calibur machine using FCS Express software (DeNovo
Software). Cells were initially gated on live cells area by
FSC x SSC analysis, then gated the CD3 positive/CD8
positive/Thy1.1 positive (staining for pmel-1 T cells),
followed by TGFβ RII levels analysis. Intracellular
IFN-γ staining was done as described previously [22].
Briefly, 1million cells were stimulated with 1 μM spe-
cific peptide (gp100(25–33)) or non-relevant peptide
Ovalbumin, plus brefeldin A (BD Pharmingen) and
50 U/ml IL-2, for six hours at 37°C in 5% CO2. Cells
were then washed with staining buffer (PBS with 3%
FBS and 0.09% sodium azide), pre-treated with anti-
FcR Ab for 10 min, and then stained with anti-CD4,
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for 30 min. Cells were then permeabilized and fixed
with Cytofix/CytoPerm (BD Pharmingen), then stained
for intracellular IFN-γ with anti-IFN-γ or a isotype
control mAb.Results
Pmel-1 CD8 T cells can be transduced to high efficiency
with a DN TGFβ retrovirus
The retroviral vector encoding the DN TGFβ RII (DN),
in which the intracellular signaling sequence was
deleted, is depicted in Figure 1A. Activated Pmel-1 sple-
nocytes can be transduced to high efficiency (70-90%)
with this vector. Shown in Figure 1B are DN-transduced
and mock-transduced Pmel-1 splenocytes stained with
an antibody for the human (not murine) TGFβ RII re-
ceptor. The right hand panel (DN Pmel-1) shows the
levels of enrichment of human DN receptor transgene
after transduction. This DN TGFβ receptor has been
shown in previous studies to inhibit TGFβ signaling.
Pmel-1 T cells, transduced with the DN receptor, did
not phosphorylate SMAD3 after incubation with ex-
ogenous TGFβ1 (Figure 1C). The proliferation of mock-
transduced, but not DN-transduced, Pmel-1 cells was
inhibited after exposure to TGFβ1 (Figure 1D). These
results confirm that this DN receptor inhibits the anti-
proliferative effects of TGFβ (12).DN TGFβ -transduced pmel-1 more effectively mediate
B16 tumor regression
Pmel-1 CD8 splenocytes express a transgenic TCR that
recognizes gp10025-33 in the context of H-2D
b; adoptive
transfer of activated Pmel-1 can mediate partial or
complete regression of established B16 melanoma in
various animal tumor models [23,24]. The B16 melan-
oma used in these experiments produced about 1 μg
TGFβ/106 tumor cells/24 hr. C57BL/6 mice bearing
small-established B16 tumors (~64 mm3) experienced
significant delay in tumor outgrowth upon adoptive
transfer of activated Pmel-1 T cells (Figure 2). A myeloa-
blative conditioning regimen of 900 cGy whole body ir-
radiation (accompanied by bone marrow rescue) creates
space in the secondary lymphoid organs enabling better
repopulation by administered T cells. Administration of
IL-2 and/or gp10025-33 peptide pulsed dendritic cell vac-
cine (gp10025-33/DC) supports the expansion and anti-
tumor activity of administered Pmel-1 T cells. Figure 2
depicts a direct comparison between DN-transduced
(80% transduction efficiency) and mock transduced
Pmel-1; 105 DN Pmel-1 produced greater tumor sup-
pression than 106 mock Pmel-1. These animals were
supported by IL-2 administration alone.DN TGFβ effector T cell function with IL-2 and/or
gp10025-33/DC support
A comparable set of experiments is shown in Figure 3 in
which DN Pmel-1 or mock Pmel-1 were administered to
B16 tumor-bearing mice that then received IL-2,
gp10025-33/DC, both or neither supporting intervention.
In Figure 3A, Pmel-1 were administered to conditioned
mice with established B16 tumors; the DN group
delayed tumor outgrowth to day 60 with neither IL-2
nor DC vaccine. The administration of IL-2 (3B),
gp10025-33/DC (3 C) or IL-2/DC (3D) clearly enhances
the antitumor activity of both mock and DN Pmel-1.
DN Pmel-1 cells have superior anti-tumor biology
in vivo compared to mock transduced Pmel in all groups
except those animals receiving IL-2/DC in which tumor
suppression for all Pmel treated mice extends to day 60.
These data are represented in Kaplan-Meier plots in
Figure 3E where a clear pattern emerges. Control mice
all die by day 24. Only 11% of mock-transduced Pmel
treated mice survived to day 120 whereas 53% of DN-
transduced Pmel mice were still alive.
Tumor infiltrating DN TGFβ pmel-1 T cells remain
activated in the tumor microenvironment
DN and mock-transduced Pmel-1 were co-adoptively
transferred to B16 tumor-bearing and non tumor-
bearing mice; we wanted to compare their relative ex-
pansion, tumor infiltration, and activation in vivo.
Tumor infiltrating and spleen repopulating Pmel-1 were
retrieved at various intervals (days 14, 21, 28 post ACT)
and evaluated for relative number and percent of cells
producing IFN-γ (by intracellular cytokine staining).
There was not a reproducible preferential expansion or
infiltration of either Pmel-1 population in the tumor or
spleen, based on total cells counts analyzed from the
harvested tissues (Additional file 1: Figure S1). However,
in replicate experiments, a higher percentage of DN
Pmel-1 retrieved from B16 tumors stained for IFN-γ. As
shown in Figure 4B, the differences were very significant
at all time points for tumor infiltrating Pmel-1, with DN
population having a several fold higher percentage of
IFN-γ production. Spleen repopulation with the DN
Pmel-1/mock Pmel-1 co-adoptive transfer also demon-
strated higher IFN-γ production among DN Pmel-1 on
days 14 and 21 but not 28, in both naïve and B16
tumor-bearing mice, and to a comparable degree. Ana-
lysis of spleen repopulation suggests that DN Pmel-1, in
general, can maintain a higher level of Th1 cytokine pro-
duction upon adoptive transfer into conditioned hosts.
A remarkable comparison is between spleen and tumor-
infiltrating Pmel-1, and the profound suppression of
cytokine production in the latter population. These find-
ings suggest that DN Pmel are functionally more active
within the tumor microenvironment.
Figure 1 Pmel-1 CD8+ T cell transduction and expression of DN TGFβ RII. A. Linear map of DN TGFβ RII retroviral vector,
TM= transmembrane region. B. Representative dot plot of mock or DN transduced Pmel-1. C. Untransduced or DN-transduced Pmel-1 T cells
were incubated in 10 ng/ml TGFβ for 0, 0.5, 1, 6, 24 hr prior to protein extraction and analyzed for expression of phosphorylated SMAD3. In the
presence of TGFβ, untransduced Pmel-1 T cells demonstrated high expression level of phosphorylated SMAD3 protein at 0.5 and 1 hr whereas
DN transduced Pmel-1 T cells did not show p-SMAD3 expression, indicating DN transgene effectively inhibits TGFβ signaling in transduced cells.
D. Absolute cell counts of Pmel-1 cells re-activated with IL-2 (50 IU/ml) and gp100 peptide (1 μg/ml) and treated with mouse TGFβ1 (10 ng/ml)
for 72 h.
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We have shown that TCR-transgenic T cells trans-
duced with a TGFβ dominant-negative receptor have
superior anti-tumor activity against B16 melanoma in
a model of adoptive cell therapy. This work extends
the findings of several other groups using an identical
DN receptor in a variety of models of auto-immunity
and tumor immunity. The novelty of this confirma-
tory report is the use of TCR-transgenic T cells that
recognize a self tumor antigen in a commonly usedpreclinical animal model. DN TGFβ-transduced Pmel-
1, on a cell for cell basis, were more than ten-fold
more potent in mediating tumor regression of estab-
lished tumors. We observed complete and durable re-
gression in some mice receiving DN Pmel-1 with neither
IL-2 nor DC vaccine support. Pmel-1 CD8 T cells
retrieved from B16 tumor microenvironment are
immunosuppressed; fewer than 10% express IFN-γ by
intracellular cytokine staining. In contrast, 25-35% of
tumor-infiltrating DN Pmel-1 continued to produce IFN-γ,
Figure 2 TGFβ insensitive Pmel-1 cells more effectively mediate B16 tumor regression. B16 tumor-bearing mice were conditioned with
900 cGy irradiation and given bone marrow support prior to adoptive transfer of either 105 or 106 mock or DN transduced Pmel-1 and IL2
support. Compared to mock transduced Pmel-1, DN Pmel-1 demonstrate better anti-tumor activity. Experiment was performed twice with similar
results.
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TGFβ is a pleiotropic cytokine which plays a signifi-
cant role in various cellular processes including cellular
proliferation, differentiation, and activation [8,25]. Mul-
tiple studies have demonstrated a direct correlation be-
tween TGFβ expression and tumor growth in melanoma
and various other types of cancer [26]. TGFβ has
an anti-proliferative effect and is considered to be a
tumor suppressor during early stages of tumor devel-
opment; however, during later stages of carcinogenesis,
large amounts of TGFβ are secreted from many
tumor types and have been implicated in immune
evasion, mainly through negative regulation of immune
effector function [27].
The DN TGFβ RII transgene has been demonstrated to
be an effective strategy to circumvent the inhibitory effect
of TGFβ. Upon TGFβ binding to the extracellular region
of the TGFβ receptor complex, intracellular kinase do-
main phosphorylates SMAD2 and SMAD3 protein, which
translocate to the nucleus along with SMAD4, forming a
complex that regulates gene expression. DN TGFβ recep-
tor II lacks the intracellular kinase domain thus inhibiting
intracellular signaling upon TGFβ binding. Mice with T
cells that express this DN receptor as a transgene could
reject various murine tumors including lymphoma and
melanoma [16]. These elegant experiments have shown
enhanced cross-presentation of tumor antigen and expan-
sion of antigen-reactive T cells. Apart from inhibiting T
cell effector function, TGFβ has an anti-proliferative effect.
In vitro, exogenous TGFβ inhibits proliferation of wild-
type T cells while DN transduced T cells retain prolifera-
tive and lytic function [12-14]. These TGFβ DN transgenic
mice, at 12 wks, develop lethal multi-organ autoimmune
disease [8,9]. This finding underscores the key role of
TGFβ in Treg maintenance of peripheral tolerance.
Several reports have demonstrated the ability of adop-
tively transferred DN CD8+ T cells to mount potent anti-tumor response against solid tumors. The anti-tumor re-
sponse is mainly attributed to increased immune effector
function of adoptively transferred T cells. Whereas wild-
type or TGFβ sensitive T cells are rendered anergic by
tumor secreting TGFβ, T cells that are insensitive to TGFβ
signaling retain their cytolytic function and demonstrate
the ability to produce IFN-γ as well as granule exocytosis
[12-15].
Natural killer and dendritic cells are also negatively
regulated by TGFβ. TGFβ inhibits expression of MHC
II, costimulatory molecules, and cytokine production by
dendritic cells. Tian et al. demonstrated that blockade of
TGFβ signaling in dendritic cells leads to enhanced anti-
tumor activity in a murine renal carcinoma vaccine
model [28].
Tumor-secreted TGFβ not only affects T cells
through direct inactivation and growth inhibition, but
also plays a significant role in the maintenance and
function of regulatory T cells [29-31]. It is well estab-
lished that TGFβ promotes generation of induced regu-
latory T cells upon TCR stimulation and supports their
survival in the periphery. Chen et al. showed that regu-
latory T cell dependent inhibition of tumor-specific
CD8+ T cell mediated cytotoxicity requires the expres-
sion of TGFβ receptor, as CD8+ T cells incapable of
TGF β signaling were resistant to suppression by regu-
latory T cells [10].
TGFβDNRII-transduced T cells are currently being
used in clinical trials for Epstein-Barr virus (EBV)-
associated malignancies Hodgkin and non-Hodgkin
lymphoma [13,14]. In preclinical models, DNtransduced
EBV-specific T cells have a functional advantage over un-
modified T cells: they were resistant to TGFβ-mediated
inhibition of proliferation cytolytic activity and mediated
superior antitumor activity in a murine tumor model.
In summary, we demonstrate that antigen-specific T
cells rendered insensitive to TGFβ through retroviral
transduction of a DN TGFβ receptor II gene mount a
Figure 3 (See legend on next page.)
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Figure 3 DN Pmel-1 mediate tumor regression without IL2 and gp10025-33/DC support. Mice bearing subcutaneous B16 tumors were
myeloablated and given BM support prior to receiving adoptive transfer of 106 mock or DN Pmel-1. Subsequently, mice received IL2 or
gp10025-33/DC support, both, or neither. Even without IL2 and gp10025-33/DC support, DN Pmel-1 mounted robust anti-tumor activity, repressing
B16 tumor outgrowth up to 90 days post tumor implantation (3A). Support with IL2, gp10025-33/DC, or both lead to better tumor protection,
however, DN Pmel-1 still demonstrate superior anti-tumor activity compared to mock Pmel-1 (3B, 3 C, 3D). E: Kaplan-Meier survival plot of mice
treated as described above.
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most likely due to the ability of TGFβ insensitive T cells
to remain active in the tumor microenvironment. Nu-
merous studies have confirmed the presence of tumor
infiltrating lymphocytes in resected cancer; however,
these CD8+ T cells are functionally anergic when ana-
lyzed ex vivo [32]. Introducing a DN TGFβ RII gene into
adoptively transferred T cells may prove to be an effectiveFigure 4 TGFβ insensitive Pmel-1 remain activated in immunosuppre
adoptive transfer of DN and mock transduced Pmel-1 to B16 tumor-bearin
lymphocytes (TILs) of treated mice were analyzed for IFN-γ production by i
6x107 splenocytes were collected on each day of experimentation. Figure 4
mixture pmel-1 injected mice stimulated with either IL2 + control OVA pep
DN TGFβ RII tumor-infiltrating lymphocytes were actively secreting IFN-γ up
(4B). In both tumor-bearing and non tumor-bearing mice (all mice received
γ on day 14 and 21 post adoptive transfer compared to mock Pmel-1 splenstrategy against tumor-mediated inactivation of infiltrating
lymphocytes.Endnote
This work was supported by R01 CA129816, P01
CA132681, the Keck Foundation, and the Joy and Jerry
Monkarsh Research Fund.ssive tumor microenvironment. On day 14, 21, and 28 post co-
g and non tumor-bearing mice, splenocytes and tumor-infiltrating
ntracellular cytokine staining. Between 2x104-3x105 TILs and 1x107-
A shows representative dot plots of TILs harvested from DN/mock
tide or IL2 +melanoma specific gp10025-33 peptide. About 25-35% of
on re-stimulation compared to about 10% of mock-transduced TILs
DC vaccinations), a higher % of DN Pmel-1 splenocytes produce IFN-
ocytes (4B). Experiment was performed twice with similar results.
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